over the forecast period.
North America accounts for larger market revenue share in global sterile injectable market
North America leads the global sterile injectable market in terms of revenue in 2016. Regions such
as Asia Pacific and Europe presented better growth opportunities for the market players owing to
conducive business policies and increased local production generic injectable . For instance, in
2013, Mylan Inc. completed the acquisition of the Agila injectables businesses from Strides Arcolab
Limited.
Get More Information about this Report @
http://www.planetmarketreports.com/reports/sterile-injectable-drugs-market-35
Competition Assessment
Key players profiles in the global sterile injectable market include:
• AbbVie Inc. U.S
• Amgen Inc. U.S
• AstraZeneca plc U.K
• Baxter International Inc. U.S
• Eli Lilly and Company U.S
• GILEAD SCIENCES, INC. U.S
• GlaxoSmithKline plc. U.K
• Johnson & Johnson Services, Inc. U.S
• Merck & Co., Inc. U.S
• Novo Nordisk A/S Denmark
• Novartis AG Switzerland
• Pfizer Inc. U.S
• F. HoffmannLa Roche AG Switzerland
• Sanofi France
Market players are focusing on mergers and acquisitions to improve their market position in sterile
injectable market. For instance, in 2016, Baxter International Inc. acquired Claris Injectables Limited,
a wholly owned subsidiary of Claris Lifesciences Limited, for total consideration of approximately
$625mn. In 2015 Pfizer Inc. acquired Hospira, Inc., world’s leading provider of injectable and
infusion technologies.
Key Findings of the Report:
• Sterile injectable market expanding at 7.3% CAGR over 2017 to 2023 to reach market value of
US$ 552 Bn by 2023
• Based on molecule type large molecules accounted for larger market share in 2016
• Oncology segment expected to be most lucrative market in global sterile injectable market
• Hospital pharmacies are prime channel for sterile drug distribution across the globe
• Players focusing on expanding geographic presence to garner market opportunities in developing
economies
Key Features of the Report: